Heartburn or acid reflux mainly affect the upper gastrointestinal tract and is linked with gastroesophageal reflux disease (GERD) and gastritis. This multi-country, multi-center observational study comprising of 18,724 patients emphasized omeprazole 40 mg as the preferred therapy for improving patient-reported outcome measures (PROMs) and quality of life in heartburn-related disorders.

To study the effectiveness of daily use of proton pump inhibitor - omeprazole 40 mg and 20 mg using PROMs in cases of heartburn due to non-erosive reflux disease, GERD, stomach inflammation, indigestion, functional heartburn, peptic ulcers.

Naïve patients aged ≥18 years with heartburn symptoms were prescribed with omeprazole. The short-form-leeds dyspepsia questionnaires (SF-LDQ), work productivity and activity impairment questionnaire (WPAI), medicine relief and, treatment satisfactory questionnaires (TSQ) were used to assess PROM.

Overall, 18,724 patients with heartburn (GERD;10,509 patients having gastritis) were prescribed omeprazole (Dr. Reddy’s omeprazole [DO]/generic omeprazole [GO]/branded omeprazole [BO]) 40 mg (as a total daily dose) and 20 mg.

Noteworthy improvement with omeprazole 40 mg compared to 20 mg in SF-LDQ, the relief obtained via medicine in heartburn patients as per the statistical comparative analysis. In the ‘a lot’ and ‘complete’ relief group, DO 20 mg had a greater improvement.

Total omeprazole dose of 40 mg on a routine basis portrayed improved efficacy than omeprazole 20 mg concerning PROM in heartburn patients.